Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on March 26, 2021. The report details the entry into a material definitive agreement regarding the company's capital raising capabilities.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the amendment of an equity distribution facility.
Material Changes
- Equity Distribution Agreement Amendment: On March 26, 2021, the Company entered into Amendment No. 1 to its existing Equity Distribution Agreement with Piper Sandler & Co.
- Offering Capacity Increase: The original agreement, dated September 11, 2019, allowed for the sale of shares with an aggregate offering price of up to $25.0 million. The amendment permits the offering of an unlimited amount of shares of common stock.
- Prospectus Supplement: The Company filed a prospectus supplement to offer up to an additional $50.0 million of shares under the amended agreement.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard terms of the equity distribution agreement. The amendment is intended to provide flexibility for future "at-the-market" offerings.
Investor Verification Checklist
- Verify the terms of the "at-the-market" offering in the filed Exhibit 10.1 (Amendment No. 1).
- Review the prospectus supplement for the specific conditions governing the additional $50.0 million offering.
- Monitor future 8-K filings for actual share issuances and proceeds generated under the amended agreement.
- Confirm the legal validity of the shares as outlined in the opinion of Dechert LLP (Exhibit 5.1).